CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study
CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study
复制标题
DOI：
10.1136/jnnp.2009.199950
复制
发表时间：
2010-10-01
影响因子：
11
通讯作者：
Mulugeta, Ezra
中科院分区：
文献类型：
--
作者：
Alves, Guido;Bronnick, Kolbjorn;Mulugeta, Ezra
背景 阿尔茨海默病 (AD) 病理学存在于相当一部分帕金森病 (PD) 患者中，尤其是早期痴呆 (PDD) 患者。 PDD 中脑脊液 (CSF) 中的淀粉样蛋白 (Aβ) 和 tau 蛋白水平发生改变，而非痴呆 PD 中 Aβ42 的水平发生中间变化。作者研究了 AD 相关的脑脊液蛋白水平是否发生改变，以及与未经治疗的早期 PD 的神经心理表现有关。方法通过电化学发光法测量 CSF 中 Aβ 42、Aβ40 和 Aβ38 的浓度，并通过 ELISA 测量 109 名新诊断的患者的脑脊液中 Aβ42、Aβ40 和 Aβ38 的浓度，并通过 ELISA 测量总 tau (T-tau) 和磷酸化 tau (P-tau) 的水平。 未经药物治疗、非痴呆、基于社区的 PD 患者接受了全面的神经心理学测试，并与 36 名年龄匹配的正常对照者和 20 名轻度 AD 受试者进行了比较。 结果 PD 患者的 A beta 42 (19%; p=0.009)、A beta 40 (15.5%; p=0.008) 和 A beta 38 (23%; p=0.004) 显着降低但不是 与对照组相比，T-tau (p=0.816) 或 P-tau (p=0.531)。 PD 中的 CSF A β 42 降低不如 AD 中显着（53%；p=0.002）。序贯回归分析表明 A beta 42 (beta=0.205; p=0.019)、A beta 40 (beta=0.378; p=0.019) 的 CSF 水平之间存在显着相关性
Background Alzheimer's disease (AD) pathology is found in a considerable portion of patients with Parkinson's disease (PD), particularly those with early dementia (PDD). Altered cerebrospinal fluid (CSF) levels of amyloid-beta (A beta) and tau proteins have been found in PDD, with intermediate changes for A beta 42 in non-demented PD. The authors investigated whether AD-related CSF protein levels are altered and relate to neuropsychological performance in early, untreated PD.Methods CSF concentrations of A beta 42, A beta 40 and A beta 38 were measured by electrochemiluminiscene and levels of total tau (T-tau) and phosphorylated tau (P-tau) by ELISA in 109 newly diagnosed, unmedicated, non-demented, community-based PD patients who had undergone comprehensive neuropsychological testing, and were compared with those of 36 age-matched normal controls and 20 subjects with mild AD.Results PD patients displayed significant reductions in A beta 42 (19%; p=0.009), A beta 40 (15.5%; p=0.008) and A beta 38 (23%; p=0.004) but not T-tau (p=0.816) or P-tau (p=0.531) compared with controls. CSF A beta 42 reductions in PD were less marked than in AD (53%; p=0.002). Sequential regression analyses demonstrated significant associations between CSF levels of A beta 42 (beta=0.205; p=0.019), A beta 40 (beta=0.378; p